Julphar Gulf Pharmaceutical Industries

Julphar is a true reflection of Ras Al Khaimah’s significant development. Established in 1980 under the guidance of H.H Sheikh Saqr Bin Mohammed Al Qasimi, we have established ourselves as a leader in production and distribution of pharmaceutical products.



Our goal is to create high-quality medicines whilst maintaining a competitive cost. We achieve this through a network of twelve world-class manufacturing plants (with further expansion planned) and a reliable logistics network which covers five continents.



We maintain a diverse product portfolio which target major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.



Highlighting our commitment to diabetes management in the region, we have also become the only company in the Middle East to produce the raw material needed to make insulin through our division dedicated to Diabetes.



With over 800 products in various dosage forms and more in the pipeline, Julphar is an example of one of the UAE’s local businesses making an impact on the global stage.

Julphar is proudly embedded in the history of Ras Al Khaimah and the United Arab Emirates. As one of the first Arab State companies and the first local pharmaceutical company in the UAE, Its tie to the region is as strong as it is significant.



Ras Al Khaimah, the UAE’s most Northern Emirate, officially became part of the UAE in 1972. This was at a time where patients were making the transition from herbal medicines to conventional medicines. The decision to start Julphar stems from a brave decision from HH Sheikh Saqr Bin Mohammed Al Qasimi, who wanted to invest in a sector which would be sustainable for their Emirate.